- Home
- CMPX vs VSTM Comparison
CMPX vs VSTM Comparison
Compare CMPX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- VSTM
- Stock Information
- Founded
- CMPX 2014
- VSTM 2010
- Country
- CMPX United States
- VSTM United States
- Employees
- CMPX N/A
- VSTM N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- VSTM Health Care
- Exchange
- CMPX Nasdaq
- VSTM Nasdaq
- Market Cap
- CMPX 291.8M
- VSTM 425.9M
- IPO Year
- CMPX N/A
- VSTM 2012
- Fundamental
- Price
- CMPX $2.62
- VSTM $4.85
- Analyst Decision
- CMPX Strong Buy
- VSTM Strong Buy
- Analyst Count
- CMPX 9
- VSTM 9
- Target Price
- CMPX $12.67
- VSTM $12.63
- AVG Volume (30 Days)
- CMPX 940.2K
- VSTM 2.4M
- Earning Date
- CMPX 08-11-2025
- VSTM 08-07-2025
- Dividend Yield
- CMPX N/A
- VSTM N/A
- EPS Growth
- CMPX N/A
- VSTM N/A
- EPS
- CMPX N/A
- VSTM N/A
- Revenue
- CMPX $850,000.00
- VSTM $10,000,000.00
- Revenue This Year
- CMPX N/A
- VSTM $129.06
- Revenue Next Year
- CMPX N/A
- VSTM $306.32
- P/E Ratio
- CMPX N/A
- VSTM N/A
- Revenue Growth
- CMPX N/A
- VSTM N/A
- 52 Week Low
- CMPX $0.77
- VSTM $2.10
- 52 Week High
- CMPX $4.08
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- CMPX 62.96
- VSTM 40.44
- Support Level
- CMPX $2.50
- VSTM $4.01
- Resistance Level
- CMPX $2.71
- VSTM $6.62
- Average True Range (ATR)
- CMPX 0.19
- VSTM 0.34
- MACD
- CMPX 0.00
- VSTM -0.03
- Stochastic Oscillator
- CMPX 72.00
- VSTM 42.00
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.